Quantum Biopharma Ltd. has announced a significant partnership with Thermo Fisher Scientific to implement a Phase 2 clinical trial for its investigational therapy, Lucid-MS, aimed at treating multiple sclerosis (MS). This collaboration marks a crucial milestone in the company's efforts to advance innovative therapies in the pharmaceutical industry, particularly in the neuroprotective space.
On October 6, 2026, Quantum Biopharma, listed on Nasdaq under the ticker QNTM, filed a report detailing the execution of a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business. This agreement will facilitate the initiation of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Lucid-MS in individuals with progressive forms of MS.
The partnership with Thermo Fisher Scientific, a leading global contract research organization, is expected to enhance Quantum's clinical development capabilities. The company has received FDA clearance to proceed with the planned Phase 2 trial, which will assess clinical and radiological endpoints relevant to disease progression and biology.
Quantum's CEO, Zeeshan Saeed, expressed enthusiasm about the collaboration, stating, "We are pleased to enter into a contract with the clinical research business of Thermo Fisher as we advance the Lucid-MS program toward Phase 2." He emphasized the importance of this next step in working with experienced partners to initiate the study.
Andrzej Chruscinski, President of Scientific and Clinical Affairs at Quantum, highlighted the innovative approach of Lucid-MS, which targets demyelination rather than merely modulating the immune system. The Phase 2 trial aims to provide valuable insights into this novel neuroprotective strategy.
According to the press release, multiple sclerosis affects approximately 2.8 million people worldwide, representing a significant healthcare challenge and market opportunity for innovative treatments. The MS therapeutic market is projected to exceed $38 billion by 2030, indicating a robust growth potential for effective therapies.
Quantum BioPharma is dedicated to developing a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders. The company's lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in the progression of multiple sclerosis.
As Quantum BioPharma embarks on this new phase of clinical development, the industry will be closely monitoring the trial's progress and its implications for the future of MS therapies. The filing does not specify what happens next, but the collaboration with Thermo Fisher Scientific positions Quantum favorably in the competitive landscape of pharmaceutical preparations.